Tank Blanketing in API Pharma Processing - Equilibar Precision Fluid Control

Tank Blanketing in API Pharma Processing

Design considerations for active pharmaceutical tank blanketing

  • schematic of API tank blanketing

In the manufacturing process for Active Pharmaceutical Ingredients (APIs), raw materials, inactive ingredients, intermediates, and excipients may be reactive with oxygen or moisture and require an inert environment. A typical solution is to add an inerting gas or tank blanketing gas into the process tank to replace the oxygen or moisture in the environment. Nitrogen blanketing, sometimes called nitrogen padding, is also helpful for reducing risk of explosion if flammable volatiles are present.

What are the design considerations for a pharmaceutical API tank blanketing system?

API pharmaceutical processing has some added complexities over biopharma processing that should be considered. For instance, solvents are commonly used and require partial pressure control to suppress evaporation. Additionally, high molarity buffers can sometimes be too aggressive for stainless steels, requiring the use of exotic metals for component construction like Hastelloy. So, in addition to the quality of the nitrogen gas source, the process parameters to consider in API blanketing are

  • flow rate of nitrogen gas
  • pressure control range
  • Automation requirements
  • chemical compatibility with volatile gases
  • cleanability requirements
  • ATEX requirements

Tank blanketing applications require precise flow and pressure control of nitrogen gas into and out of the process tank to keep the pressure inside the tank at the desired setpoint. A typical nitrogen padding system supplies nitrogen to the tank with a pressure reducing valve (PRV) or tank blanketing valve until it reaches the pressure setpoint. When conditions change and tank pressure exceeds the setpoint, blanket gas is removed from the tank using a back pressure regulator (BPR) or “de-padding” regulator. Below is a schematic showing how it might be designed.

schematic of API tank blanketing

Schematic example of API tank blanketing

Equilibar Back Pressure Regulators are an excellent solution in API tank blanketing applications

Equilibar back pressure regulators are widely used in tank blanketing applications to relieve excess pressure in the tank. Why are Equilibar BPRs well-suited for tank blanketing in API?

  1. They can be designed to specifically meet the parameters required in API pharmaceutical processing.
    • Hastelloy material can be used for cases where corrosive volatile gases in the API process could be in the gas stream with the nitrogen.
    • The Equilibar valve can provide significantly lower control ranges as compared to traditional spring solutions, offering users ultra-low pressure ranges (inWC/mbar) without exhibiting over-pressure behavior
    • Design options are available if CIP or SIP cleanability is required.
    • Equilibar BPRs can be controlled manually or electronically.
    • The pilot setpoint regulator for the BPR can be chosen based on ATEX considerations. It can also be placed in a location outside an ATEX area.
  2. The multiple orifice design and flexible diaphragm allow the Equilibar BPR to adjust instantaneously to changes in pressure inside the tank without hysteresis or cracking pressure.
  3. Equilibar BPRs work across a wide range of flow rates and are often chosen over traditional valves for their Cv rangeability.

Contact an Equilibar application engineer to discuss your tank blanketing application.

Sanitary BPR for tank blanketing

FDO6 Sanitary back pressure regulator where CIP cleanability is required

Request a Quote Download Brochure

GSD6 with Model 10 pilot regulator

Equilibar GSD6 back pressure regulator where sanitary design is not required

Contact Us Download Brochure

Work Categories
Equilibar News
PUK magazine cover with stainless steel device

Journal article focuses on oligonucleotide production using pressure control with built in dampener

Oligonucleotide drugs are made up of short sections of genetic sequences and are used to target disorders in the genetic code. The first drug of this type was used in 1998 during the AIDS epidemic.  Since then, the field has accelerated rapidly and today many oligonucleotide drugs are in clinical trials, promising improvements in treatment Read More

Read More